MaxCyte Q1 revenue $9.7M (-7% YoY); net loss narrows to $4.8M; board authorizes $10M buyback

MAXCYTE, INC.

Core revenue $6.2M (-25% YoY); SPL-related revenue rose to $3.4M from $2.1M.
Net loss improved to $4.8M from $10.3M; EBITDA loss $5.1M vs $11.2M.
Reiterated FY 2026 revenue guidance $30-32M (core $25-27M, SPL ~$5M).
Board authorized $10M share repurchase program over one year.
Cash, equivalents and investments $147.7M as of March 31, 2026.

item 2.02item 7.01item 9.01

Source: SEC EDGAR

accession 0001104659-26-059399

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.